How long can you live with advanced lung cancer using Pralsetinib?

Pralsetinib demonstrated robust and durable responses in the RET fusion-positive NSCLC treatment group. These data support early biomarker testing in all patients with metastatic NSCLC before treatment initiation. Platinib is currently approved in the United States for the treatment of metastatic RET fusion-positive NSCLC and advanced or metastatic RET-altered thyroid cancer, and in China for platinum-based chemotherapy for locally advanced or metastatic NSCLC.

In a major study, platinib was effective in shrinking tumor size in patients with RET fusion-positive non-small cell lung cancer who had not received prior treatment or who had received platinum-based chemotherapy and was not compared with any other treatment or placebo. The results showed that approximately 72% of previously untreated patients had a complete or partial response to platinib treatment. About 59% of patients who received platinib after platinum-based chemotherapy had a complete or partial response to platinib treatment.

It is understood that the original drug Platinib has been launched in China, but it has not yet entered the scope of medical insurance. The price of each box of 100mg*120 tablets may be around 60,000 yuan, which is expensive. The price of the European version of 100mg*60 capsules sold overseas may be around 40,000 yuan per box, and the price of the American version may be around 150,000 yuan per box (prices may fluctuate due to exchange rates). The ingredients of domestic and foreign original drugs are basically the same. There is currently no generic version of Platinib available on the market. Please consult your medical consultant for specific prices and drug details.